Abbott Laboratories (ABT) Akcija Kursas
Abbott Laboratories Kursas
Per pastaruosius 19 metus Abbott Laboratories pajamos augo 3,6 % kasmet ir pasiekė 44,33 mlrd. USD. Pelnas akcijai augo 6,6 % per metus per pastaruosius 19 metus. Abbott Laboratories grynoji marža 14,7 % yra sumažėjo palyginti su 16,4 % prieš kelerius metus. Esama kaina dividendo pajamingumas yra apie 2,29 %. Išmokų koeficientas yra apie 63 % pelno. Dividendas augo 3,8 % per metus per pastaruosius 19 metus. Abbott Laboratories 12 mėn. konsensuso tikslinė kaina yra 120,00 USD, apie virš kursą 16,5 %. Iš 33 analitikų 26 rekomenduoja pirkti — bendras konsensusas yra Pirkti.
Abbott Laboratories akcijos kaina
Gaukite šiuos duomenis per Eulerpool API
100 000 užklausų/mėn. nemokamai · be kortelės
Abbott Laboratories akcija ir akcijų analizė
Dažnai užduodami klausimai apie Abbott Laboratories akciją
Abbott Laboratories is a renowned healthcare company with a strong business model focused on providing a diverse range of medical products, diagnostics, nutritional supplements, and pharmaceuticals. By combining technological advancements with innovative research, Abbott aims to enhance the quality of life for individuals worldwide. With a comprehensive portfolio spanning diverse healthcare sectors, including diagnostics, nutrition, diabetes care, medical devices, and branded generic pharmaceuticals, Abbott Laboratories strives to improve patient outcomes and deliver sustainable growth. Through its commitment to scientific excellence and dedication to meeting evolving healthcare needs, Abbott Laboratories has established itself as a trusted leader in the global healthcare industry.
Abbott Laboratories is primarily active in the healthcare industry.
The main competitors of Abbott Laboratories in the market are Johnson & Johnson, Pfizer, and Roche Holding AG.
Abbott Laboratories is a renowned American healthcare company, known for providing a diverse range of medical, pharmaceutical, and nutritional products. Founded in 1888 by Dr. Wallace C. Abbott, the company initially focused on producing pharmaceuticals, including the widely successful alkaloid-based pain reliever, Abbott's ABC Liniment. Over the years, Abbott Laboratories has expanded its portfolio, venturing into areas such as diagnostics, medical devices, and nutrition. The company's commitment to innovation is evident through breakthroughs like the development of the first HIV blood-screening test. Today, Abbott Laboratories continues to play a crucial role in improving health outcomes worldwide, with its cutting-edge technology and a focus on delivering quality healthcare solutions.
Abbott Laboratories has achieved several significant milestones throughout its history. One major milestone was the development and commercialization of the first-ever HIV blood screening test, which greatly contributed to safer transfusions and the prevention of the spread of HIV. Additionally, Abbott Laboratories introduced breakthrough medical devices, such as the FreeStyle® Libre system, a continuous glucose monitoring system for diabetes management. The company also played a crucial role in the fight against COVID-19 by developing rapid diagnostic tests for the virus. Furthermore, Abbott Laboratories has consistently been recognized for its commitment to innovation and sustainability, making it a leading healthcare company globally.
Abbott Laboratories is primarily present in multiple countries and regions worldwide. The company operates in more than 160 countries, including the United States, Canada, Europe, Asia-Pacific, Latin America, and the Middle East. With a strong global footprint, Abbott Laboratories has established itself as a leading healthcare company in various markets, delivering innovative medical products, diagnostics, nutritionals, and pharmaceuticals to improve people's health and well-being.
Abbott Laboratories is committed to its core values of putting patients first, serving customers with innovative solutions, and operating with integrity in all aspects of its business. The company's corporate philosophy centers around improving life through the development of groundbreaking technologies and products. Abbott Laboratories prides itself on its dedication to delivering reliable healthcare solutions, fostering collaboration with healthcare professionals, and investing in research and development to address unmet medical needs. With a focus on providing high-quality and accessible healthcare options, Abbott Laboratories strives to create positive impacts in communities worldwide through its diverse portfolio of medical devices, diagnostics, nutrition, and pharmaceutical products.
Analitikai šiuo metu nustato vidutinę Abbott Laboratories akcijos tikslinę kainą 120,85 USD (mediana: 120,00 USD), t. y. +16,3 % palyginti su paskutine kaina. Konsensusas pagrįstas 33 analitikų reitingais.
33 analitikai šiuo metu vertina Abbott Laboratories akciją: 26 rekomenduoja pirkti, 7 laikyti ir 0 parduoti. 2026 m. analitikai tikisi, kad Abbott Laboratories gaus 49,98 mlrd. USD pajamų ir 5,52 USD pelno akcijai.
Pagal dabartinį kursą Abbott Laboratories akcija kainuoja 93,81 EUR (103,00 USD).
Abbott Laboratories akcija (ABT) kotiruojama 9 biržose, įskaitant: NYSE (ABT), London (0Q15.L), SIX (Zürich) (ABT.SW), XETRA (ABL.DE), Frankfurt (ABL.F), München (ABL.MU), Düsseldorf (ABL.DU), Hamburg (ABL.HM).
Abbott Laboratories is a global company specializing in the development, manufacturing, and marketing of health products and services. Its business model is divided into different divisions that focus on the needs of patients, doctors, and healthcare systems. The divisions of Abbott Laboratories include Diagnostics, Medical Devices, Nutrition, and Pharmaceutical. The company aims to continuously develop innovative technologies and products to improve healthcare, and it offers a wide range of services and support programs for patients. Abbott Laboratories has established a strong market position and global presence in over 160 countries since its establishment in 1888. It also pursues a successful acquisition strategy to expand its product portfolio, such as the acquisition of St. Jude Medical in 2017 to enhance its cardiovascular products and services. Overall, Abbott Laboratories aims to improve healthcare and meet the needs of patients, doctors, and healthcare systems through its comprehensive strategy focused on developing innovative products, expanding into new markets, and increasing efficiency.
tikėtina pelnas Abbott Laboratories yra 49,98 mlrd. USD. Šis skaičius grindžiamas dabartiniais finansiniais duomenimis ir atspindi įmonės verslo rezultatus.
tikėtina grynasis pelnas Abbott Laboratories yra 9,64 mlrd. USD. Grynasis pelnas atspindi įmonės pelningumą po visų išlaidų atimties.
Kainų ir nuomos santykis (KGV) Abbott Laboratories šiuo metu yra 18,66. KGV lygina dabartinę akcijos kainą su pelnu už akciją ir padeda investuotojams įvertinti Abbott Laboratories akcijos vertę.
Kainų ir pardavimų santykis (KUV) Abbott Laboratories šiuo metu yra 3,60. KUV lygina rinkos kapitalizaciją su metinėmis pajamomis ir yra Abbott Laboratories akcijos įvertinimo metrika.
Eulerpool kokybės balas Abbott Laboratories yra 6/10.
Abbott Laboratories ISIN yra US0028241000. ISIN (International Securities Identification Number) yra pasaulinė unikali vertybinių popierių identifikacijos sistema.
Abbott Laboratories WKN yra 850103. WKN (Wertpapierkennnummer) yra šešiaženklė vokiška vertybinių popierių identifikacijos sistema.
Abbott Laboratories prekybos žymė yra ABT. Ši biržos žymė naudojama Abbott Laboratories akcijoms prekiauti biržoje.
Abbott Laboratories akcija
Abbott Laboratories Pagrindiniai konkurentai
Abbott Laboratories Biržos simbolis
Abbott Laboratories FIGI
Visos Abbott Laboratories pagrindinės charakteristikos ir giluminė analizė
Mūsų akcijų analizė Abbott Laboratories akcijai apima svarbius finansinius rodiklius, tokius kaip apyvarta, pelnas, P/E santykis, P/S santykis, EBIT, taip pat informaciją apie dividendes. Be to, mes nagrinėjame aspektus, tokius kaip akcijos, rinkos kapitalizacija, skolos, nuosavas kapitalas ir įsipareigojimai Abbott Laboratories. Jei ieškote išsamesnės informacijos šiais klausimais, mūsų poskyriuose galite rasti išsamias analizes:


